Skip to main content
. 2020 Oct 15;12(10):6351–6365.

Figure 2.

Figure 2

Trametinib increases the density of oligodendrocytes in the traumatic area of TBI mice. (A) On the left, red signal indicates the immunofluorescence staining of oligodendrocyte marker oligo2 in the traumatic area of normal control, TBI control and trametinib-treated (1 mg/kg/day) TBI mice at days 3 and 7 post TBI. On the right, bar graph shows the quantification of oligo2-positive cells within the traumatic area. *P<0.05. Scale bar =50 μm. (B) Western blot analysis of MBP and MOG protein expression levels in murine TBI brain tissues (same treatment as A) at days 3 and 7 posts TBI. (C) Relative gene expression of oligodendrocyte specific genes in murine TBI brain tissues (same treatment as A) at days 7 post TBI using qPCR. *P<0.05, ***P<0.001. TM, trametinib; MBP, myelin basic protein; MOG, Myelin oligodendrocyte glycoprotein; PDGFa, Platelet Derived Growth Factor Subunit A; SOX10, SRY-Box Transcription Factor 10; CSPG4, Chondroitin sulfate proteoglycan 4; CLDN11, Claudin 11.